Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF03016324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study.
BMJ Neurol Open
August 2025
Department of Neurology, Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine (Punan Hospital in Pudong New District, Shanghai), Shanghai, China.
Introduction: Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12-20% of generalised MG (gMG) patients despite immunotherapies. Plasma exchange (PLEX) transiently depletes pathogenic mediators, while neonatal Fc receptor antagonists (eg, efgartigimod) offer novel therapeutic potential. Both PLEX and efgartigimod require adjunctive non-steroidal immunosuppressive therapy (NSIST) for sustained remission.
View Article and Find Full Text PDFRelationship of coffee consumption with colonic diverticulosis.
BMC Gastroenterol
August 2025
Department of Gastroenterology, Antalya Training and Research Hospital, University of Health Sciences, Varlik mah. Kazim Karabekir cad, Antalya, 07100, Turkey.
Background: Diverticulosis is the most common benign pathology of the colon. Genetics, inflammation, neuromuscular abnormalities, colonic motility and lifestyle including dietary habits play roles in disease pathogenesis. Coffee is one of the most commonly consumed beverages worldwide and exerts antiinflammatory functions in the human body as well as affecting colonic motility and neuromuscular physiology of the gastrointestinal system.
View Article and Find Full Text PDFChanges in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
J Neurol
June 2025
Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Background: The efficacy and safety of complement component 5 inhibitor zilucoplan in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG) were assessed in two double-blind studies (NCT03315130/NCT04115293 [RAISE]). During these studies and the first 12 weeks of the open-label extension study, RAISE-XT, corticosteroid and non-steroidal immunosuppressive therapy (NSIST) doses were kept stable; thereafter doses could be changed at the investigator's discretion. We evaluated corticosteroid and NSIST dose changes in patients with gMG during zilucoplan treatment in RAISE-XT.
View Article and Find Full Text PDFComplement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis.
Ther Adv Neurol Disord
May 2025
Department of Neuroscience, Università Cattolica del Sacro Cuore, L.go F. Vito, 1 00168 Rome, Italy.
Background: Standard management of generalized myasthenia gravis associated with anti-acetylcholine receptor autoantibodies (AChR-gMG) includes corticosteroids and nonsteroidal immunosuppressants. Complement inhibitors (CI) represent a more tailored therapeutic strategy. Real-world data on the steroid-sparing efficacy of CI remain limited.
View Article and Find Full Text PDFTelitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect.
Front Immunol
April 2025
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction: Myasthenia Gravis (MG) is an autoimmune disorder characterized by impaired neuromuscular junction (NMJ) transmission. Current treatments for MG include steroids and nonsteroidal immunosuppressive therapies (NSISTs). However, approximately 20% of patients show a poor response to these therapies, which are often associated with significant side effects.
View Article and Find Full Text PDF